Akeso, Inc. announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug application for AK117, a next generation CD47 monoclonal antibody in combination with azacitidine for treatment of patients with newly diagnosed higher-risk myelodysplastic syndromes.
